Your browser doesn't support javascript.
loading
[68Ga]Ga-DOTATATE-avid tumor volume, uptake and inflammation-based index correlate with survival in neuroendocrine tumor patients treated with [177Lu]Lu-DOTATATE PRRT.
Pauwels, Elin; Dekervel, Jeroen; Verslype, Chris; Clement, Paul M; Dooms, Christophe; Baete, Kristof; Goffin, Karolien; Jentjens, Sander; Van Laere, Koen; Van Cutsem, Eric; Deroose, Christophe M.
Afiliación
  • Pauwels E; Nuclear Medicine, University Hospitals Leuven Leuven, Belgium.
  • Dekervel J; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven Leuven, Belgium.
  • Verslype C; Digestive Oncology, University Hospitals Leuven Leuven, Belgium.
  • Clement PM; Digestive Oncology, University Hospitals Leuven Leuven, Belgium.
  • Dooms C; General Medical Oncology, University Hospitals Leuven Leuven, Belgium.
  • Baete K; Respiratory Oncology, University Hospitals Leuven Leuven, Belgium.
  • Goffin K; Nuclear Medicine, University Hospitals Leuven Leuven, Belgium.
  • Jentjens S; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven Leuven, Belgium.
  • Van Laere K; Nuclear Medicine, University Hospitals Leuven Leuven, Belgium.
  • Van Cutsem E; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven Leuven, Belgium.
  • Deroose CM; Nuclear Medicine, University Hospitals Leuven Leuven, Belgium.
Am J Nucl Med Mol Imaging ; 12(5): 152-162, 2022.
Article en En | MEDLINE | ID: mdl-36419585
To meet the increasing demand for PRRT in the treatment of patients with inoperable/disseminated well-differentiated neuroendocrine tumors (NETs) and to guide optimization strategies, adequate and accessible predictive tools that allow to stratify patients who will benefit from treatment from those who will not are becoming indispensable. Previously, we have investigated the role of baseline [68Ga]Ga-DOTATOC PET tumor uptake and volumetric parameters and a blood-derived inflammatory biomarker, the inflammation-based index (IBI), for outcome prediction in NET patients treated with [90Y]Y-DOTATOC. In this retrospective study in 83 NET patients treated with [177Lu]Lu-DOTATATE in a routine clinical setting, we aimed to evaluate the generalizability of our previous findings to [177Lu]Lu-DOTATATE treatment combined with a pre-therapeutic [68Ga]Ga-DOTATATE PET. A semi-automatic customized SUV threshold-based approach was used for tumor delineation. The previously identified SUVmean cut-off of 13.7 for better survival could not be applied to this patient cohort. Instead, a more optimal cut-off could be identified: an SUVmean lower or equal than 11.2 was associated with worse overall survival (OS) (hazard ratio (HR) 2.28; P = 0.008). Also in line with our previous study, a [68Ga]Ga-DOTATATE-avid tumor volume (TV) higher than 672 mL and an elevated baseline IBI were correlated with worse OS (HR 3.13 (P = 0.0001) and HR 2.00 (P = 0.034), respectively). Multivariate analysis confirmed independent associations between OS and baseline IBI (P = 0.032), SUVmean (P = 0.027) and [68Ga]Ga-DOTATATE-avid TV (P = 0.001). Taking baseline IBI, [68Ga]Ga-DOTATATE-avid TV and [68Ga]Ga-DOTATATE uptake into account may help guide PRRT treatment decisions.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Am J Nucl Med Mol Imaging Año: 2022 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Am J Nucl Med Mol Imaging Año: 2022 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Estados Unidos